News from biolinerx ltd. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 20, 2023, 07:00 ET BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

- Received FDA Approval of APHEXDA® (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and...

Nov 13, 2023, 07:00 ET BioLineRx to Report Third Quarter 2023 Results on November 20, 2023

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...

Sep 19, 2023, 07:00 ET BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...

Sep 11, 2023, 07:00 ET BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company focused on certain cancers and rare diseases, today announced that...

Aug 22, 2023, 07:00 ET BioLineRx to Report Second Quarter 2023 Results on August 30, 2023

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial stage biopharmaceutical company pursuing life-changing therapies for certain cancers and rare...

Jul 17, 2023, 07:00 ET BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate Motixafortide

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial stage biopharmaceutical company pursuing life-changing therapies for certain cancers and ...

May 17, 2023, 07:00 ET BioLineRx to Report First Quarter 2023 Results on May 24, 2023

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, announced today that it will...

Apr 25, 2023, 07:00 ET BioLineRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has received formal ...

Mar 22, 2023, 07:00 ET BioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates

- Announced FDA Acceptance of APHEXDA® (motixafortide) New Drug Application (NDA) in Stem Cell Mobilization with Prescription Drug User Fee Act...

Dec 20, 2022, 07:00 ET BioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced results from the...

Nov 28, 2022, 16:30 ET BioLineRx to Participate in the 12th Annual LifeSci Partners Corporate Access Event

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that management...

Nov 15, 2022, 07:00 ET BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate and Portfolio Updates

- Announced FDA acceptance of APHEXDA® (motixafortide) New Drug Application (NDA) in stem cell mobilization with Prescription Drug User Fee Act...

Nov 10, 2022, 07:01 ET BioLineRx Announces U.S. FDA Acceptance of New Drug Application for APHEXDA® (motixafortide) in Stem Cell Mobilization

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that the U.S. Food...

Nov 03, 2022, 09:11 ET BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma and Program for Potential Motixafortide Indication Expansion in Gene Therapy at the 64th American Society of Hematology (ASH) Annual Meeting

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that its full...

Sep 27, 2022, 07:00 ET BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced its U.S....

Sep 19, 2022, 08:00 ET BioLineRx Announces $15 Million Registered Direct Offering

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has entered ...

Sep 15, 2022, 07:00 ET BioLineRx Announces $40 Million Non-Dilutive Debt Financing Agreement with Kreos Capital

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that the Company...

Sep 12, 2022, 07:00 ET BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that the Company...

Aug 16, 2022, 07:00 ET BioLineRx Reports Second Quarter 2022 Financial Results and Provides Corporate Update

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today reports its financial results ...

Aug 11, 2022, 07:00 ET BioLineRx to Report Second Quarter 2022 Results on August 16, 2022

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, announced today it will release its ...

Jun 28, 2022, 07:00 ET BioLineRx Announces Collaboration Agreement with GenFleet Therapeutics to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC)

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that the Company has ...

Jun 16, 2022, 07:00 ET BioLineRx Announces Appointment of Commercial Strategy and Operations Veteran Holly W. May as Chief Commercial Officer

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that the Company has ...

May 11, 2022, 07:00 ET BioLineRx Reports First Quarter 2022 Financial Results and Provides Corporate Update

- On track to submit New Drug Application to FDA for Motixafortide in stem cell mobilization (SCM) for autologous stem cell transplantation in...

Mar 16, 2022, 07:00 ET BioLineRx Reports Year-End 2021 Financial Results and Provides Corporate Update

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results...

Mar 10, 2022, 07:00 ET BioLineRx to Report 2021 Annual Results on March 16, 2022

BioLineRx Ltd. (NASDAQ: BLRX), (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its ...